comparemela.com

Latest Breaking News On - Epmetko - Page 1 : comparemela.com

Scottish Medicines Consortium recommends Merck s Tepmetko

Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients - News - PharmaTimes

United kingdomNorthern irelandBrian clarkStuart hillNational institute for healthScotland cancer centreEuropean medicines agencyScottish medicines consortiumRegulatory agencyNational instituteCare excellenceMerck united kingdomBeatson west

Merck: European Commission Approves TEPMETKO (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

TEPMETKO is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping,

United statesEgbert smitAnne marie bairdAndrew patersonEuropean commissionDrug administrationNetherlands cancer instituteEuropean economic areaProfessor egbert smitNetherlands cancerNew england journalLung cancerChief marketing officerProduct characteristicsEnglj medAccessed february

TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO®

United statesMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useDanny bar zoharGlobal headNew england journalLung cancerMerck press releasesMedia contactRal met inhibitor

Merck: TEPMETKO (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

TEPMETKO is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harboring alterations leading to METex14 skipping Not intended

United statesMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useDanny bar zoharGlobal headNew england journalLung cancerMerck press releases

Merck KGaA: TEPMETKO Receives CHMP Positive Opinion In Adult Patients With Advanced NSCLC

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Merck KGaA (MKGAY.PK) announced the CHMP of the European Medicines Agency adopted a positive opinion recommending approval of once-daily oral TEPMETKO as monotherapy

Bruxelles capitaleMerck kgaEuropean medicines agencyEuropean commission

vimarsana © 2020. All Rights Reserved.